Mitochondrial Function & Energy Results
SS-31 (Elamipretide) is a mitochondria-targeting peptide that binds cardiolipin in the inner mitochondrial membrane, restoring electron transport chain efficiency and reducing oxidative stress. Research documents improvements in exercise capacity, cardiac function, and cellular energy production.
Source: Stealth BioTherapeutics Phase II Clinical Trials (MMPOWER-3, TAZPOWER) | Individual results vary.
Important: Results shown are from clinical trials and represent averages. Individual results vary significantly based on dose, underlying mitochondrial health, and adherence. This page is for informational purposes only. Consult a qualified healthcare professional before use.
SS-31 rapidly concentrates in the inner mitochondrial membrane due to its cationic amphiphilic structure. Cardiolipin binding stabilizes cristae morphology and begins restoring electron transport chain organization. No visible changes are expected at this stage.
Cardiolipin stabilization reduces electron leak from the respiratory chain, decreasing mitochondrial ROS production. Subjects in research protocols often report improved energy levels and reduced fatigue during this period, reflecting improved cellular ATP production efficiency.
Improved mitochondrial function translates to measurable improvements in exercise capacity. Clinical trials documented increases in 6-minute walk distance and peak oxygen consumption (VO2 max). Recovery time after exertion typically improves during this window.
In cardiac research models, improvements in left ventricular function and remodeling markers become measurable. Muscle tissue biopsies in preclinical studies show restored mitochondrial morphology, with more elongated, interconnected mitochondrial networks replacing the fragmented phenotype seen in aging.
Continued administration maintains mitochondrial health improvements. Long-term studies in aged animal models show sustained reductions in oxidative damage biomarkers and preserved exercise capacity. Human clinical trials have documented maintained improvements in quality of life scores and functional capacity at 12+ weeks.
SS-31 (Elamipretide; D-Arg-2'6'-Dmt-Lys-Phe-NH₂) is a tetrapeptide that selectively concentrates in the inner mitochondrial membrane (IMM) due to its alternating cationic and aromatic residues. Its primary target is cardiolipin, a phospholipid unique to the IMM that is essential for organizing the respiratory chain supercomplexes (Complexes I–IV) into efficient electron transfer units.
In aging and disease states, cardiolipin undergoes oxidative modification, causing respiratory chain disorganization, increased electron leak, and elevated reactive oxygen species (ROS) production. SS-31 binds to cardiolipin, stabilizing its structure and restoring supercomplex organization. This reduces electron leak, increases ATP synthesis efficiency, and decreases mitochondrial ROS — addressing the root cause of age-related mitochondrial dysfunction rather than simply scavenging ROS downstream.
Unlike antioxidants that passively neutralize ROS, SS-31 acts upstream by preventing ROS generation. This mechanistic distinction is why SS-31 has shown efficacy in clinical settings where antioxidant supplements have generally failed.
Improvements in exercise capacity and energy levels are often reported within 2–4 weeks. Cardiac function improvements in clinical trials were documented at 4–12 weeks.
SS-31 selectively concentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing the electron transport chain and reducing mitochondrial ROS production. This restores cellular energy production efficiency.
SS-31 has been studied in Phase II clinical trials for heart failure with preserved ejection fraction (HFpEF). Results showed improvements in 6-minute walk distance and quality of life scores.
Preclinical research suggests SS-31 can partially reverse age-related mitochondrial dysfunction. Studies in aged rodents showed improvements in mitochondrial morphology, reduced ROS, and improved exercise tolerance.
Both target mitochondria, but through different mechanisms. SS-31 binds cardiolipin in the inner mitochondrial membrane, while MitoQ is a coenzyme Q10 analogue that acts as an antioxidant. SS-31 has more robust clinical trial data.
Purgo Labs provides HPLC-verified, third-party tested SS-31 (Elamipretide) for legitimate research purposes. Every batch includes a certificate of analysis.
Shop SS-31 at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.